{
    "2020-05-26": [
        [
            {
                "time": "2020-05-26",
                "original_text": "格隆汇港股聚焦(5.26)︱比亚迪半导体拟增资扩股引入战投金山软件一季度经营利润同比大增124%",
                "features": {
                    "keywords": [
                        "比亚迪半导体",
                        "增资扩股",
                        "战投",
                        "金山软件",
                        "经营利润",
                        "同比大增"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "半导体",
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-05-26",
                "original_text": "【国信医药】新冠检测专题(2)：海外爆发，Q2弹性可期",
                "features": {
                    "keywords": [
                        "新冠检测",
                        "海外爆发",
                        "Q2弹性"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-05-26",
                "original_text": "疫情下的生物科技故事很燃：“新冠救星”还是“资本泡沫”",
                "features": {
                    "keywords": [
                        "疫情",
                        "生物科技",
                        "新冠救星",
                        "资本泡沫"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-05-27",
                "original_text": "A股头条之上市公司（5.27）",
                "features": {
                    "keywords": [
                        "A股",
                        "上市公司"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-05-26",
                "original_text": "医疗新基建方向明确 机构称将拉动相关设备需求",
                "features": {
                    "keywords": [
                        "医疗新基建",
                        "设备需求"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "基建"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-05-26",
                "original_text": "复星医药(02196.HK)比卡鲁胺片通过仿制药一致性评价",
                "features": {
                    "keywords": [
                        "复星医药",
                        "比卡鲁胺片",
                        "仿制药",
                        "一致性评价"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-05-26",
                "original_text": "每经数说丨5月上半月新药研发：复宏汉霖与2药企合作研发新冠全人源抗体药物，君实生物与礼来达成2.55亿美元新冠抗体合作",
                "features": {
                    "keywords": [
                        "新药研发",
                        "复宏汉霖",
                        "君实生物",
                        "礼来",
                        "新冠抗体",
                        "合作"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-05-26",
                "original_text": "智通港股通持股分析|5月26日",
                "features": {
                    "keywords": [
                        "港股通",
                        "持股分析"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-05-26",
                "original_text": "复星医药(02196.HK)获郭广昌增持82.2万股",
                "features": {
                    "keywords": [
                        "复星医药",
                        "郭广昌",
                        "增持"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}